Cynosure Inc. (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The Company operates through aesthetic treatment products and services segment. It markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology. The Company's product portfolio utilizes a range of energy sources, including Alexandrite, diode, neodymium-doped yttrium aluminum garnet (Nd: YAG), pulse dye, Q-switched lasers, intense pulsed light and RF technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: CYNO
- CUSIP: 23257720
- Previous Close: $66.30
- 50 Day Moving Average: $51.78
- 200 Day Moving Average: $49.04
- 52-Week Range: $38.01 - $66.65
- Trailing P/E Ratio: 102.00
- Foreward P/E Ratio: 32.50
- P/E Growth: 1.93
- Market Cap: $1.57B
- Outstanding Shares: 23,631,000
- Beta: 1.65
- Net Margins: 3.56%
- Return on Equity: 6.86%
- Return on Assets: 5.35%
Companies Related to Cynosure:
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 3.28%
- Quick Ratio: 2.54%
What is Cynosure's stock symbol?
Cynosure trades on the NASDAQ under the ticker symbol "CYNO."
Where is Cynosure's stock going? Where will Cynosure's stock price be in 2017?
7 analysts have issued 12-month price targets for Cynosure's shares. Their forecasts range from $40.00 to $66.00. On average, they expect Cynosure's share price to reach $57.71 in the next twelve months.
When will Cynosure announce their earnings?
Cynosure is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.
What are analysts saying about Cynosure stock?
Here are some recent quotes from research analysts about Cynosure stock:
According to Zacks Investment Research, "Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light. " (1/9/2017)
Brean Capital analysts commented, "Centene reported 1Q16 results this morning and put to bed most concerns regarding the Health Net acquisition that closed in late March. Revenue was about $7 billion, in line with our estimate after reflecting the delayed close of the Health Net acquisition. Importantly, the company’s individual exchange business appears to be performing nicely. Health Net’s individual exchange business does not appear to be problematic. The company wrote off Health Net’s outstanding receivables (relating to the 3Rs) and will record balance sheet adjustments to Health Net’s days in claims payables in 2Q16. On the surface, it appears as though Centene has its hands firmly around the acquisition. CNC shares remain very attractive and offer 35% upside potential to our price target (even after reflecting today’s strength in the share price)." (4/27/2016)
Who owns Cynosure stock?
Cynosure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock, Inc (12.00%), Dimensional Fund Advisors LP (5.10%), Loomis Sayles & Co. L P (2.66%), State Street Corp (2.52%), Disciplined Growth Investors Inc. MN (1.47%) and Russell Investments Group Ltd. (1.32%). Company insiders that own Cynosure stock include Brian M Barefoot, Douglas J Delaney, Ettore V Biagioni, Michael R Davin and Timothy W Baker.
Who sold Cynosure stock? Who is selling Cynosure stock?
Cynosure's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Two Sigma Investments LP, Allianz Asset Management AG, GSA Capital Partners LLP, Thompson Siegel & Walmsley LLC, AQR Capital Management LLC, Loomis Sayles & Co. L P and Frontier Capital Management Co. LLC. Company insiders that have sold Cynosure stock in the last year include Brian M Barefoot, Douglas J Delaney, Michael R Davin and Timothy W Baker.
Who bought Cynosure stock? Who is buying Cynosure stock?
Cynosure's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Newtyn Management LLC, Disciplined Growth Investors Inc. MN, Dimensional Fund Advisors LP, State Street Corp, ING Groep NV, Micawber Capital LLC and Menta Capital LLC.
How do I buy Cynosure stock?
Shares of Cynosure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cynosure stock cost?
One share of Cynosure stock can currently be purchased for approximately $66.30.